1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsDoD Rare Cancers, Idea Development Award is sponsored by Dept. of the Army -- USAMRAA. Supports early-stage, high-impact research on rare cancers with required preliminary data and strong disease rationale.
Clinical trials are not allowed; research must address at least one of three focus areas (biology, pre-clinical models, therapy).
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
DoD Rare Cancers, Idea Development Award by Dept. of the Army -- USAMRAA | Atom Grants DoD Rare Cancers, Idea Development Award The DoD FY25 Rare Cancers Idea Development Award supports early-stage research with preliminary data that could significantly impact rare cancer treatment. Funder: Dept.
of the Army -- USAMRAA Due Dates: July 1, 2025 (Pre-Application) | October 6, 2025 (Full Application, by invitation) Funding Amounts: Up to $490,000 total costs (direct + indirect) per award | Up to 3 years | ~14 awards, $6. 86M total program Summary: Supports early-stage, high-impact research on rare cancers with required preliminary data and strong disease rationale.
Key Information: Clinical trials are not allowed; research must address at least one of three focus areas (biology, pre-clinical models, therapy). This opportunity, offered by the Department of Defense's Rare Cancers Research Program (RCRP), Idea Development Award (IDA), is designed to support innovative, early-stage research projects that have the potential to yield impactful data and open new avenues for rare cancer investigation.
The program specifically targets research that could lead to significant advances in understanding, diagnosing, or treating rare cancers—defined as those affecting six or fewer persons per 100,000 per year in the United States. Projects must be supported by preliminary data with a disease-specific rationale, though the data do not have to be from the exact rare cancer type proposed.
The research should have a high potential impact on rare cancer outcomes and the patient community. Applications are encouraged to include exploratory aims or sub-aims to support discovery-driven research. Clinical trials are not permitted under this mechanism.
Research must address at least one of the following focus areas: Biology: Disease-defining molecular pathways, cell context, and microenvironment. Pre-Clinical Research Model: Development and validation of rare tumor-specific models for clinical trial readiness. Therapy: Identification of novel therapeutic strategies, including drug repurposing.
See the full grant listing
According to the current listing, eligibility includes: Independent investigators at or above the level of postdoctoral fellow (or equivalent) affiliated with an eligible organization. Nonprofits are eligible. Confirm the full requirements in the official notice before applying.
The current listing shows up to $490,000 total costs. Verify award ceilings, matching requirements, and allowable costs in the official notice.
DoD Rare Cancers, Idea Development Award is funded by Dept. of the Army -- USAMRAA. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals.Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories:• The Established Investigator category is for independent investigators at all academic levels, or equivalent• The New Investigator – Early-Stage category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators.• The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Established Investigators.Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required for all applications. Clinical trials or clinical trial aims are not allowed. Funding Opportunity Number: HT942526DMDRPIDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $2.5M total program funding.
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award (CTRA) supports advanced translational research to accelerate promising ideas in Duchenne muscular dystrophy (DMD) research toward clinical applications. Research must address at least one of the FY26 CTRA Focus Areas. Research projects investigating therapies that will be efficacious across the life span are strongly encouraged.Distinctive Features: The FY26 CTRA offers two funding levels:• Funding Level 1 to support smaller, less complex preclinical and/or clinical research.• Funding Level 2 to support larger, more complex preclinical and/or clinical research.The FY26 CTRA also offers a Partnering PI Option (PPIO) to support meaningful and productive partnerships between two investigators collaborating on the proposed research project. The PPIO has two eligibility categories:• Early-Career Partnering PI category for an independent, early-career investigator within 10 years of their first faculty appointment (or equivalent) by the time of application submission.• Established Interdisciplinary Partnering PI for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy, seeking to transition to a career in DMD, thereby bringing their expertise to the field.Preliminary data are required for all applications. Pilot clinical trials and clinical trial readiness studies to better inform development of drugs, devices, and other interventions are allowed. Funding Opportunity Number: HT942526DMDRPCTRA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $8.5M total program funding.
DoW Duchenne Muscular Dystrophy, Idea Development Award is sponsored by Dept. of the Army -- USAMRAA. Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation.
After SBIR reauthorization, the U.S. Army released five new small-business topics under Army FUZE — Ka-Band metamaterial radar, a Li-ion 6T battery open topic, in-transit-visibility blockchain, modular UAS payloads, and the xTech|Phantum prize competition. Awards run from $150K to $300K per Phase I. But the bigger story is the Army's shift from funding parts to funding whole systems. Here is what each topic funds and how to compete.
Read articleDARPA transferred its first autonomous-ready H-60Mx Black Hawk to the Army on March 20, capping a decade of ALIAS research. Now the same technology underpins an SBIR XL opportunity for small businesses building wildfire autonomy.
Read article